The data also demonstrated that combining anti-CD39, the chemotherapeutic agent gemcitabine, and anti-PD-L1 controlled tumor growth and increased survival better than monotherapy or anti-PD-L1 with gemcitabine in murine colorectal carcinoma tumors[90]. Here, CD274 is linked to colorectal carcinoma.